Lesions of the adrenal cortex

Archives of Pathology and Laboratory Medicine

Volumn 132, Issue 8, 2008, Pages 1263-1271

  McNicol, Anne Marie ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; CORTICOTROPIN; SEX HORMONE;

ADRENAL CORTEX; ADRENAL CORTEX ADENOMA; ADRENAL CORTEX CARCINOMA; ADRENAL CORTEX TUMOR; CONGENITAL ADRENAL HYPERPLASIA; CUSHING SYNDROME; DIFFERENTIAL DIAGNOSIS; FAMILIAL CANCER; HISTOLOGY; HORMONE RELEASE; HUMAN; IMMUNOHISTOCHEMISTRY; ONCOCYTOMA; PRIMARY HYPERALDOSTERONISM; REVIEW; STRESS; TUMOR DIAGNOSIS;

ADRENAL CORTEX; ADRENAL CORTEX NEOPLASMS; ADRENAL GLAND DISEASES; GROWTH; HUMANS; IMMUNOHISTOCHEMISTRY; PROGNOSIS;

EID: 49449096426     PISSN: 00039985     EISSN: 15432165     Source Type: Journal    
DOI: None     Document Type: Review

References (126)

1. Stocco DM. Recent advances in the role of StAR. Rev Reprod. 1998;3:82-85.
2. l'Allemand D, Penhoat A, Blum W, Saez JM. Is there a local IGF-system in human adrenocortical cells? Mol Cell Endocrinol. 1998;140:169-173.
3. Albertin G, Forneris M, Aragona F, Nussdorfer GG. Expression of adrenomedullin and its receptors in the human adrenal cortex and aldosteronomas. Int J Mol Med. 2001;8:423-426.
4. Vanttinen T, Liu J, Kuulasmaa T, Kivinen P, Voutilainen R. Expression of activin/inhibin signaling components in the human adrenal gland and the effects of activins and inhibins on adrenocortical steroidogenesis and apoptosis. J Endocrinol. 2003;178:479-489.
5. Haidan A, Bornstein SR, Liu Z, Walsh LP, Stocco DM, Ehrhart-Bornstein M. Expression of adrenocortical steroidogenic acute regulatory (StAR) protein is influenced by chromaffin cells. Mol Cell Endocrinol. 2000;165:25-32.
6. Li Q, Johansson H, Grimelius L. Innervation of human adrenal gland and adrenal cortical lesions. Virchows Arch. 1999;435:580-589.
7. McNicol AM, Richmond J, Charlton BG. A study of general innervation of the human adrenal cortex using PGP 9.5 immunohistochemistry. Acta Anat. 1994;151:120-123.
8. Parker TL, Kesse WK, Mohamed AA, Afework M. The innervation of the mammalian adrenal gland. J Anat. 1993;183:265-276.
9. Thomas M, Keramidas M, Monchaux E, Feige JJ. Dual hormonal regulation of endocrine tissue mass and vasculature by adrenocorticotropin in the adrenal cortex. Endocrinology. 2004;145:4320-4329.
10. Bland ML, Desclozeaux M, Ingraham HA. Tissue growth and remodeling of the embryonic and adult adrenal gland. Ann N Y Acad Sci. 2003;995:59-72.
11. Keegan CE, Hammer GD. Recent insights into organogenesis of the adrenal cortex. Trends Endocrinol Metab. 2002;13:200-208.
12. Beuschlein F, Keegan CE, Bavers DL, et al. SF-1, DAX-1, and acd: molecular determinants of adrenocortical growth and steroidogenesis. Endocr Res. 2002;28:597-607.
13. Wright NA, Voncina D, Morley AR. An attempt to demonstrate cell migration from the zona glomerulosa in the prepubertal male rat adrenal cortex. J Endocrinol. 1973;59:451-459.
14. McNicol AM, Duffy AE. A study of cell migration in the adrenal cortex of the rat using bromodeoxyuridine. Cell Tissue Kinet. 1987;20:519-526.
15. Morley SD, Viard I, Chung BC, Ikeda Y, Parker KL, Mullins JJ. Variegated expression of a mouse steroid 21-hydroxylase/beta-galactosidase transgene suggests centripetal migration of adrenocortical cells. Mol Endocrinol. 1996;10:585-598.
16. Mitani F, Mukai K, Miyamoto H, Suematsu M, Ishimura Y. The undifferentiated cell zone is a stem cell zone in adult rat adrenal cortex. Biochim Biophys Acta. 2003;1619:317-324.
17. Wyllie AH, Kerr JF, Macaskill IA, Currie AR. Adrenocortical cell deletion: the role of ACTH. J Pathol. 1973;111:85-94.
18. Sasano H, Imatani A, Shizawa S, Suzuki T, Nagura H. Cell proliferation and apoptosis in normal and pathologic human adrenal. Mod Pathol. 1995;8:11-17.
19. Ennen WB, Levay-Young BK, Engeland WC. Zone-specific cell proliferation during adrenocortical regeneration after enucleation in rats. Am J Physiol Endocrinol Metab. 2005;289:E883-891.
20. Nussdorfer G, Mazzocchi G, Rebonato L. Long-term trophic effect of ACTH on rat adrenocortical cells: an ultrastructural, morphometric and autoradiographic study. Z Zellforsch Mikrosk Anat. 1971;115:30-45.
21. Malendowicz LK. Correlated stereological and functional studies on the long-term effect of ACTH on rat adrenal cortex. Folia Histochem Cytobiol. 1986;24:203-211.
22. Hornsby PJ. Regulation of adrenocortical cell proliferation in culture. Endocr Res. 1984;10:259-281.
23. Bicknell AB, Lomthaisong K, Woods RJ, et al. Characterization of a serine protease that cleaves pro-gamma-melanotropin at the adrenal to stimulate growth. Cell. 2001;105:903-912.
24. Baccaro RB, Mendonca PO, Torres TE, Lotfi CF. Immunohistochemical Jun/ Fos protein localization and DNA synthesis in rat adrenal cortex after treatment with ACTH or FGF2. Cell Tissue Res. 2007;328:7-18.
25. Spencer SJ, Rabinovici J, Mesiano S, Goldsmith PC, Jaffe RB. Activin and inhibin in the human adrenal gland: regulation and differential effects in fetal and adult cells. J Clin Invest. 1992;90:142-149.
26. Merke DP, Bornstein SR. Congenital adrenal hyperplasia. Lancet. 2005;365:2125-2136.
27. Stratakis CA, Rennert OM. Congenital adrenal hyperplasia: molecular genetics and alternative approaches to treatment. Crit Rev Clin Lab Sci. 1999;36:329-363.
28. Jaresch S, Kornely E, Kley HK, Schlaghecke R. Adrenal incidentaloma and patients with homozygous or heterozygous congenital adrenal hyperplasia. J Clin Endocrinol Metab. 1992;74:685-689.
29. Murakami C, Ishibashi M, Kondo M, et al. Adrenal myelolipoma associated with congenital adrenal 21-hydroxylase deficiency. Intern Med. 1992;31:803-806.
30. Umpierrez MB, Fackler S, Umpierrez GE, Rubin J. Adrenal myelolipoma associated with endocrine dysfunction: review of the literature. Am J Med Sci. 1997;314:338-341.
31. Bornstein SR, Stratakis CA, Chrousos GP. Adrenocortical tumors: recent advances in basic concepts and clinical management. Ann Intern Med. 1999;130:759-771.
32. Muscatelli F, Strom TM, Walker AP, et al. Mutations in the DAX-1 gene give rise to both X-linked adrenal hypoplasia congenita and hypogonadotropic hypogonadism. Nature. 1994;372:672-676.
33. Vallette-Kasic S, Brue T, Pulichino AM, et al. Congenital isolated adrenocorticotropin deficiency: an underestimated cause of neonatal death, explained by TPIT gene mutations. J Clin Endocrinol Metab. 2005;90:1323-1331.
34. Andrioli M, Giraldi FP, Cavagnini F. Isolated corticotrophin deficiency. Pituitary. 2006;9:289-295.
35. Selva KA, LaFranchi SH, Boston B. A novel presentation of familial glucocorticoid deficiency (FGD) and current literature review. J Pediatr Endocrinol Metab. 2004;17:85-92.
36. Tsigos C, Arai K, Hung W, Chrousos GP. Hereditary isolated glucocorticoid deficiency is associated with abnormalities of the adrenocorticotropin receptor gene. J Clin Invest. 1993;92:2458-2461.
37. Carr I. The human adrenal cortex at the time of death. J Pathol Bacteriol. 1959;78:533-541.
38. Willenberg HS, Bornstein SR, Dumser T, et al. Morphological changes in adrenals from victims of suicide in relation to altered apoptosis. Endocr Res. 1998;24:963-967.
39. Rich AR. A peculiar type of adrenal cortical damage associated with acute infections and its possible relation to circulatory collapse. Bull Johns Hopkins Hosp. 1944;74:1-15.
40. Enberg U, Volpe C, Hamberger B. New aspects on primary aldosteronism. Neurochem Res. 2003;28:327-332.
41. Fiquet-Kempf B, Launay-Mignot P, Bobrie G, Plouin PF. Is primary aldosteronism underdiagnosed in clinical practice? Clin Exp Pharmacol Physiol. 2001;28:1083-1086.
42. Melby JC. Diagnosis of hyperaldosteronism. Endocrinol Metab Clin North Am. 1991;20:247-255.
43. Gordon RD, Klemm SA, Tunny TJ, Stowasser M. Primary aldosteronism: hypertension with a genetic basis. Lancet. 1992;340:159-161.
44. Omura M, Sasano H, Fujiwara T, Yamaguchi K, Nishikawa T. Unique cases of unilateral hyperaldosteronemia due to multiple adrenocortical micronodules, which can only be detected by selective adrenal venous sampling. Metabolism. 2002;51:350-355.
45. Stowasser M, Gunasekera TG, Gordon RD. Familial varieties of primary aldosteronism. Clin Exp Pharmacol Physiol. 2001;28:1087-1090.
46. Torpy DJ, Gordon RD, Lin JP, et al. Familial hyperaldosteronism type II: description of a large kindred and exclusion of the aldosterone synthase (CYP11B2) gene. J Clin Endocrinol Metab. 1998;83:3214-3218.
47. Pascoe L, Curnow KM, Slutsker L, et al. Glucocorticoid-suppressible hyperaldosteronism results from hybrid genes created by unequal crossovers between CYP11B1 and CYP11B2. Proc Natl Acad Sci U S A. 1992;89:8327-8331.
48. Sturrock ND, Morgan L, Jeffcoate WJ. Autonomous nodular hyperplasia of the adrenal cortex: tertiary hypercortisolism? Clin Endocrinol (Oxf). 1995;43:753-758.
49. Irie J, Kawai K, Shigematsu K, et al. Adrenocorticotropic hormone-independent bilateral macronodular adrenocortical hyperplasia associated with Cushing's syndrome. Pathol Int. 1995;45:240-246.
50. Aiba M, Hirayama A, Iri H, et al. Adrenocorticotropic hormone-independent bilateral adrenocortical macronodular hyperplasia as a distinct subtype of Cushing's syndrome: enzyme histochemical and ultrastructural study of four cases with a review of the literature. Am J Clin Pathol. 1991;96:334-340.
51. Christopoulos S, Bourdeau I, Lacroix A. Aberrant expression of hormone receptors in adrenal Cushing's syndrome. Pituitary. 2004;7:225-235.
52. Mazzuco TL, Chabre O, Feige JJ, Thomas M. Aberrant expression of human luteinizing hormone receptor by adrenocortical cells is sufficient to provoke both hyperplasia and Cushing's syndrome features. J Clin Endocrinol Metab. 2006;91:196-203.
53. Bourdeau I, Antonini SR, Lacroix A, et al. Gene array analysis of macronodular adrenal hyperplasia confirms clinical heterogeneity and identifies several candidate genes as molecular mediators. Oncogene. 2004;23:1575-1585.
54. Chabre O, Liakos P, Vivier J, et al. Gastric inhibitory polypeptide (GIP) stimulates cortisol secretion, cAMP production and DNA synthesis in an adrenal adenoma responsible for food-dependent Cushing's syndrome. Endocr Res. 1998;24:851-856.
55. Chabre O, Liakos P, Vivier J, et al. Cushing's syndrome due to a gastric inhibitory polypeptide-dependent adrenal adenoma: insights into hormonal control of adrenocortical tumorigenesis. J Clin Endocrinol Metab. 1998;83:3134-3143.
56. Sandrini F, Stratakis C. Clinical and molecular genetics of Carney complex. Mol Genet Metab. 2003;78:83-92.
57. Reinhard C, Saeger W, Schubert B. Adrenocortical nodules in post-mortem series: development, functional significance, and differentiation from adenomas. Gen Diagn Pathol. 1996;141:203-208.
58. Dobbie JW. Adrenocortical nodular hyperplasia: the ageing adrenal. J Pathol. 1969;99:1-18.
59. Hedeland H, Östberg G, Hökfelt B. On the prevalence of adrenocortical adenomas in autopsy material in relation to hypertension and diabetes. Acta Med Scand. 1968;184:211-214.
60. Grumbach MM, Biller BM, Braunstein GD, et al. Management of the clinically inapparent adrenal mass ("incidentaloma"). Ann Intern Med. 2003;138:424-429.
61. Bovio S, Cataldi A, Reimondo G, et al. Prevalence of adrenal incidentaloma in a contemporary computerized tomography series. J Endocrinol Invest. 2006;29:298-302.
62. Kloos RT, Gross MD, Francis IR, Korobkin M, Shapiro B. Incidentally discovered adrenal masses. Endocr Rev. 1995;16:460-483.
63. Beuschlein F, Reincke M. Adrenocortical tumorigenesis. Ann N Y Acad Sci. 2006;1088:319-334.
64. Nawar R, Aron D. Adrenal incidentalomas - a continuing management dilemma. Endocr Relat Cancer. 2005;12:585-598.
65. Saeger W, Reinhard K, Reinhard C. Hyperplastic and tumorous lesions of the adrenals in an unselected autopsy series. Endocr Pathol. 1998;9:235-239.
66. Watanabe N, Tsunoda K, Sasano H, et al. Bilateral aldosterone-producing adenomas in two patients diagnosed by immunohistochemical analysis of steroidogenic enzymes. Tohoku J Exp Med. 1996;179:123-129.
67. Ueda Y, Tanaka H, Murakami H, et al. A functioning black adenoma of the adrenal gland. Intern Med. 1997;36:398-402.
68. Brennan MF. Adrenocortical carcinoma. CA Cancer J Clin. 1987;37:348-353.
69. Correa P, Chen VW. Endocrine gland cancer. Cancer. 1995;75:338-352.
70. Lubitz JA, Freeman L, Okun R. Mitotane use in inoperable adrenal cortical carcinoma. JAMA. 1973;223:1109-1112.
71. Hutter AMJ, Kayhoe DE. Adrenal cortical carcinoma. Am J Med. 1966;41:572-580.
72. Ibanez ML. The pathology of adrenal cortical carcinomas: study of 22 cases. In: Endocrine and Nonendocrine Hormone-Producing Tumors. Chicago, Ill: Year Book Medical Publishers; 1971:231-239.
73. MacFarlane DA. Cancer of the adrenal cortex: the natural history, prognosis and treatment in a study of fifty-five cases. Ann Royal Coll Surg Engl. 1958;23:155-186.
74. Flynn SD, Murren JR, Kirby WM, Honig J, Kan L, Kinder BK. P-glycoprotein expression and multidrug resistance in adrenocortical carcinoma. Surgery. 1992;112:981-986.
75. Haak HR, van Seters AP, Moolenaar AJ, Fleuren GJ. Expression of P-glycoprotein in relation to clinical manifestation, treatment and prognosis of adrenocortical cancer. Eur J Cancer. 1993;7:1036-1038.
76. Murakoshi M, Osamura RY, Yoshimura S, Watanabe K. Immunolocalization of glutathione-peroxidase (GSH-PO) in human adrenal gland - studies on adrenocortical adenomas associated with primary aldosteronism and Cushing's syndrome. Tokai J Exp Clin Med. 1995;20:89-97.
77. El Naggar AK, Evans DB, Mackay B. Oncocytic adrenal cortical carcinoma. Ultrastruct Pathol. 1991;15:549-556.
78. Hough AJ, Hollifield JW, Page DL, Hartmann WH. Prognostic factors in adrenal cortical tumours. Am J Clin Pathol. 1979;72:390-399.
79. Van Slooten H, Schaberg A, Smeenk D, Moolenaar AJ. Morphologic characteristics of benign and malignant adrenocortical tumors. Cancer. 1985;55:766-773.
80. Weiss LM, Medeiros LJ, Vickery AL Jr. Pathologic features of prognostic significance in adrenocortical carcinoma. Am J Surg Pathol. 1989;13:202-206.
81. Weiss LM. Comparable histologic study of 43 metastasizing and non metastasizing adrenocortical tumors. Am J Surg Pathol. 1984;8:163-169.
82. Aubert S, Wacrenier A, Leroy X, et al. Weiss system revisited: a clinicopathologic and immunohistochemical study of 49 adrenocortical tumors. Am J Surg Pathol. 2002;26:1612-1619.
83. McNicol AM, Struthers AJ, Nolan CE, Hermans J, Haak HR. Proliferation in adrenocortical tumors: correlation with clinical outcome and p53 status. Endocr Pathol. 1997;8:29-36.
84. Sasano H, Suzuki T, Moriya T. Discerning malignancy in resected adrenocortical neoplasms. Endocr Pathol. 2001;12:397-406.
85. Gicquel C, Le Bouc Y. Molecular markers for malignancy in adrenocortical tumors. Horm Res. 1997;47:269-272.
86. Ilvesmaki V, Kahri AI, Miettinen PJ, Voutilainen R. Insulin-like growth factors (IGFs) and their receptors in adrenal tumors: high IGF-II expression in functional adrenocortical carcinomas. J Clin Endocrinol Metab. 1993;77:852-858.
87. Barzon L, Chilosi M, Fallo F, et al. Molecular analysis of CDKN1C and TP53 in sporadic adrenal tumors. Eur J Endocrinol. 2001;145:207-212.
88. McNicol AM, Nolan CE, Struthers AJ, Farquharson MA, Hermans J, Haak HR. Expression of p53 in adrenocortical tumours: clinicopathological correlations. J Pathol. 1997;181:146-152.
89. Ohgaki H, Kleihues P, Heitz PU. p53 mutations in sporadic adrenocortical tumors. Int J Cancer. 1993;54:408-410.
90. Komminoth P, Roth J, Schroder S, Saremaslani P, Heitz PU. Overlapping expression of immunohistochemical markers and synaptophysin mRNA in pheochromocytomas and adrenocortical carcinomas: implications for the differential diagnosis of adrenal gland tumors. Lab Invest. 1995;72:424-431.
91. Arola J, Liu J, Heikkila P, Voutilainen R, Kahri A. Expression of inhibin alpha in the human adrenal gland and adrenocortical tumors. Endocr Res. 1998;24:865-867.
92. Munro LM, Kennedy A, McNicol AM. The expression of inhibin/activin subunits in the human adrenal cortex and its tumours. J Endocrinol. 1999;161:341-347.
93. Ghorab Z, Jorda M, Ganjei P, Nadji M, Melan A. (A103) is expressed in adrenocortical neoplasms but not in renal cell and hepatocellular carcinomas. Appl Immunohistochem Mol Morphol. 2003;11:330-333.
94. Shibata H, Ikeda Y, Mukai T, et al. Expression profiles of COUP-TF, DAX-1, and SF-1 in the human adrenal gland and adrenocortical tumors: possible implications in steroidogenesis. Mol Genet Metab. 2001;74:206-216.
95. Sasano H, Suzuki T, Moriya T. Recent advances in histopathology and immunohistochemistry of adrenocortical carcinoma. Endocr Pathol. 2006;17:345-354.
96. Haak HR, Fleuren GJ. Neuroendocrine differentiation of adrenocortical tumors. Cancer. 1995;75:860-864.
97. Gicquel C, Leblond-Francillard M, Bertagna X, et al. Clonal analysis of human adrenocortical carcinomas and secreting adenomas. Clin Endocrinol (Oxf). 1994;40:465-477.
98. Beuschlein F, Reincke M, Karl M, et al. Clonal composition of human adrenocortical neoplasms. Cancer Res. 1994;54:4927-4932.
99. Kjellman M, Kallioniemi OP, Karhu R, et al. Genetic aberrations in adrenocortical tumors detected using comparative genomic hybridization correlate with tumor size and malignancy. Cancer Res. 1996;56:4219-4223.
100. Sidhu S, Marsh DJ, Theodosopoulos G, et al. Comparative genomic hybridization analysis of adrenocortical tumors. J Clin Endocrinol Metab. 2002;87:3467-3474.
101. Russell AJ, Sibbald J, Haak H, Keith WN, McNicol AM. Increasing genome instability in adrenocortical carcinoma progression with involvement of chromosomes 3, 9 and X at the adenoma stage. Br J Cancer. 1999;81:684-689.
102. Gicquel C, Bertagna X, Gaston V, et al. Molecular markers and long-term recurrences in a large cohort of patients with sporadic adrenocortical tumors. Cancer Res. 2001;61:6762-6767.
103. Srivastava S, Zou Z, Pirollo K, Blattner W, Chang EH. Germline transmission of a mutated p53 gene in a cancer-prone family with Li-Fraumeni syndrome. Nature. 1990;348:747-749.
104. Reincke M, Karl M, Travis WH, et al. p53 mutations in human adrenocortical neoplasms: immunohistochemical and molecular studies. J Clin Endocrinol Metab. 1994;78:790-794.
105. Latronico AC, Pinto EM, Domenice S, et al. An inherited mutation outside the highly conserved DNA-binding domain of the p53 tumor suppressor protein in children and adults with sporadic adrenocortical tumors. J Clin Endocrinol Metab. 2001;86:4970-4973.
106. Moul JW, Bishoff JT, Theune SM, Chang EH. Absent ras gene mutations in human adrenal cortical neoplasms and pheochromocytomas. J Urol. 1993;149:1389-1394.
107. Yashiro T, Hara H, Fulton NC, Obara T, Kaplan EL. Point mutations of ras genes in human adrenal cortical tumors: absence in adrenocortical hyperplasia. World J Surg. 1994;18:455-460; discussion 460-451.
108. Lin SR, Tsai JH, Yang YC, Lee SC. Mutations of K-ras oncogene in human adrenal tumours in Taiwan. Br J Cancer. 1998;77:1060-1065.
109. Liu J, Voutilainen R, Kahri AI, Heikkila P. Expression patterns of the cmyc gene in adrenocortical tumors and pheochromocytomas. J Endocrinol. 1997;152:175-181.
110. Heppner C, Reincke M, Agarwal SK, et al. MEN1 gene analysis in sporadic adrenocortical neoplasms. J Clin Endocrinol Metab. 1999;84:216-219.
111. Li M, Squire JA, Weksberg R. Molecular genetics of Wiedemann-Beckwith syndrome. Am J Med Genet. 1998;79:253-259.
112. Gicquel C, Raffin-Sanson ML, Gaston V, et al. Structural and functional abnormalities at 11p15 are associated with the malignant phenotype in sporadic adrenocortical tumors: study on a series of 82 tumors. J Clin Endocrinol Metab. 1997;82:2559-2565.
113. Ilvesmaki V, Liu J, Heikkila P, Kahri AI, Voutilainen R. Expression of insulin-like growth factor binding protein 1-6 genes in adrenocortical tumors and pheochromocytomas. Horm Metab Res. 1998;30:619-623.
114. Weber MM, Auernhammer CJ, Kiess W, Engelhardt D. Insulin-like growth factor receptors in normal and tumorous adult human adrenocortical glands. Eur J Endocrinol. 1997;136:296-303.
115. McCluggage WG, Burton J, Maxwell P, Sloan JM. Immunohistochemical staining of normal, hyperplastic, and neoplastic adrenal cortex with a monoclonal antibody against alpha inhibin. J Clin Pathol. 1998;51:114-116.
116. Latronico AC. Role of ACTH receptor in adrenocortical tumor formation. Braz J Med Biol Res. 2000;33:1249-1252.
117. Bamberger CM, Else T, Bamberger AM, et al. Telomerase activity in benign and malignant adrenal tumors. Exp Clin Endocrinol Diabetes. 1999;107:272-275.
118. Mannelli M, Gelmini S, Arnaldi G, et al. Telomerase activity is significantly enhanced in malignant adrenocortical tumors in comparison to benign adrenocortical adenomas. J Clin Endocrinol Metab. 2000;85:468-470.
119. Bernini GP, Moretti A, Viacava P, et al. Apoptosis control and proliferation marker in human normal and neoplastic adrenocortical tissues. Br J Cancer. 2002;86:1561-1565.
120. Giordano TJ, Thomas DG, Kuick R, et al. Distinct transcriptional profiles of adrenocortical tumors uncovered by DNA microarray analysis. Am J Pathol. 2003;162:521-531.
121. de Fraipont F, El Atifi M, Cherradi N, et al. Gene expression profiling of human adrenocortical tumors using complementary deoxyribonucleic acid microarrays identifies several candidate genes as markers of malignancy. J Clin Endocrinol Metab. 2005;90:1819-1829.
122. Sasano H, Suzuki T, Sano T, Kameya T, Sasano N, Nagura H. Adrenocortical oncocytoma: a true nonfunctioning adrenocortical tumor. Am J Surg Pathol. 1991;15:949-956.
123. Lin BT, Bonsib SM, Mierau GW, Weiss LM, Medeiros LJ. Oncocytic adrenocortical neoplasms: a report of seven cases and review of the literature. Am J Surg Pathol. 1998;22:603-614.
124. Xiao GQ, Pertsemlidis DS, Unger PD. Functioning adrenocortical oncocytoma: a case report and review of the literature. Ann Diagn Pathol. 2005;9:295-297.
125. Golkowski F, Buziak-Bereza M, Huszno B, et al. The unique case of adrenocortical malignant and functioning oncocytic tumour. Exp Clin Endocrinol Diabetes. 2007;115:401-404.
126. Bishop E, Eble JN, Cheng L, et al. Adrenal myelolipomas show nonrandom X-chromosome inactivation in hematopoietic elements and fat: support for a clonal origin of myelolipomas. Am J Surg Pathol. 2006;30:838-843.